Laboratory Requirements Sample Clauses

Laboratory Requirements. 1. Urine Testing In testing urine samples, the testing laboratory shall test specifically for those drugs and classes of drugs and adulterants employing the test methodologies and cutoff levels covered in the DOT Regulations 49 CFR, Part 40.
Sample 1Sample 2Sample 3See All (15)
AutoNDA by SimpleDocs
Laboratory Requirements. The Navajo Nation adopts the certified laboratory lists maintained by the USEPA or any state with primacy over that state's drinking water program, as they may be amended from time to time. Public water system owners or operators are required to use a certified laboratory from such lists in contracting for laboratory services. The Director may maintain a service contract with one or more certified laboratories to meet this requirement.
Sample 1Sample 2
Laboratory Requirements. Intractable pain patients require regular laboratory testing (e.g. analysis of saliva, urine, and/or blood). Patients who do not obtain or do not consent to the required testing may be discharged from the program.
Sample 1
Laboratory Requirements. NO CHANGE F. Non-Suspicion-Based Post-Accident Testing NO CHANGE G. Substance Abuse Professional (SAP) NO CHANGE
Sample 1
Laboratory Requirements. All testing will be conducted by third party, independent laboratories unless otherwise mutually agreed by the Parties. The Parties shall designate one or more laboratory(ies) for testing and mutually develop protocols and other technical requirements for sampling and testing. Pre-approved laboratories include Soil Control Laboratories of Watsonville, California and Midwest Laboratories of Omaha, Nebraska. Laboratory testing is at Owner’s expense. Bulk Density Determination for Soil Amendments & Other Materials (compost, solid manures, biosolids, SSO, etc) Materials
Sample 1
Laboratory Requirements. This section specifies the minimum requirements that must be met to provide data of known and usable quality to RWQCB and USEPA in support of the SGV and SFV investigations. These requirements include a laboratory certification/ PE program, QA/ QC documentation, and data validation. Laboratories selected for the project must be capable of providing the appropriate analytical detection limits, reporting limits, required turnaround times, project quality control , and data deliverables required by this QAPP. The laboratory m ust have the demonstrated ability to analyze samples of similar type, quantity, and concentrations to be subcontracted. Prior to work on a project, the laboratory will provide:  MDL studies and laboratory -specific quantitation limits at or below the project -specific screening levels; soils sample re sults will be reported on a dry -weight basis.  Minimum QA/ QC criteria for initial and continuing calibration and interference check samples.  Minimum QA/ QC criteria for surrogate recoveries, laboratory control sampl es, blanks, MS/ MSDs indicating that the methods selected for performing analysis can be met. The analytical laboratories selected to perform samples analysis shall be certified by the SWRCB through the Environmental Laboratory Accreditation Program (ELAP) for each required method. Data whose quality do not meet the requirements of this document, regardless of laboratory cer tification, shall be excluded. These requirements apply to onsite mobile laboratories as well as offsite, fixed laboratories. Mobile lab oratories are expected to adhere to all of the specifications of the RWQCB quality program as presented in this QAPP and associated guidance documents. Method modifications or other deviations from QAPP requirements required due to the specialized nature of field laboratory operations must be detailed in the facility -specific work plan. Mobile laboratories must be certified though the Environmental Laboratory Accreditation Program. The use of mobile laboratories shal l be documented in the facility -specific work plan. The mobile laboratory quality assurance plan should be provided as part of the facility -specific work plan. The facility -specific work plan should include a plan for collection of split samples for analysis by a fixed laboratory at a frequency o f 10 percent of the total number of sample s collected when a mobile laboratory is employed . In addition, facilities that use mobile laboratories, RWQCB wil...
Sample 1
Laboratory Requirements. The sampling plan should name the laboratory to be utilized to analyze samples and their qualifications; (H) SAMPLE HANDLING: Sample preservation and other handling practices should be described; Health and Safety Plan: The Sampling Plan shall also include a description of the Health and Safety Plan of the Consultant addressing suspected hazards and risks; levels of protective clothing or equipment to be worn; decontamination procedures; and documentation of the appropriate health and safety training given to the sampling crew; (I)
Sample 1
AutoNDA by SimpleDocs
Laboratory Requirements. The laboratory shall possess the appropriate well-documented procedures, instrumentation, and trained personnel to perform the necessary analyses included in the scope of the project in the frame of required time schedule. The laboratory shall possess a radioactive materials handling license for the samples to be analyzed and will be able to prove experience in performing the same or similar analyses. It shall also fulfill requirements for laboratories which are qualified to provide analyses of non- active waste due to their classification [24]. It shall have an active and fully documented QA program in place, complying with the objectives determined by the DQO process. The QA program should include laboratory organizational structure; personnel qualifications; written standard operating procedures and instructions; inter - and intralaboratory performance analyses; design control to define the flow of samples through the laboratory; a corrective action plan; and an internal audit program. Additionally, the laboratory shall count on the capacity to provide the results on time.
Sample 1
Laboratory Requirements 
Sample 1Sample 2Sample 3

Related to Laboratory Requirements

  • Regulatory Requirements Each Party’s obligations under this Agreement shall be subject to its receipt of any required approval or certificate from one or more Governmental Authorities in the form and substance satisfactory to the applying Party, or the Party making any required filings with, or providing notice to, such Governmental Authorities, and the expiration of any time period associated therewith. Each Party shall in good faith seek and use its Reasonable Efforts to obtain such other approvals. Nothing in this Agreement shall require Developer to take any action that could result in its inability to obtain, or its loss of, status or exemption under the Federal Power Act or the Public Utility Holding Company Act of 2005 or the Public Utility Regulatory Policies Act of 1978, as amended.

  • Additional Regulatory Requirements Notwithstanding anything contained in this Agreement to the contrary, it is understood and agreed that the Bank (or any of its successors in interest) shall not be required to make any payment or take any action under this Agreement if:

  • Statutory Requirements All statutory requirements for the valid consummation by the Company of the transactions contemplated by this Agreement shall have been fulfilled. All authorizations, consents and approvals of all governments and other persons required to be obtained in order to permit consummation by the Company of the transactions contemplated by this Agreement shall have been obtained.

  • Compliance with Regulatory Requirements Upon demand by Lender, Borrower shall reimburse Lender for Lender’s additional costs and/or reductions in the amount of principal or interest received or receivable by Lender if at any time after the date of this Agreement any law, treaty or regulation or any change in any law, treaty or regulation or the interpretation thereof by any Governmental Authority charged with the administration thereof or any other authority having jurisdiction over Lender or the Loans, whether or not having the force of law, shall impose, modify or deem applicable any reserve and/or special deposit requirement against or in respect of assets held by or deposits in or for the account of the Loans by Lender or impose on Lender any other condition with respect to this Agreement or the Loans, the result of which is to either increase the cost to Lender of making or maintaining the Loans or to reduce the amount of principal or interest received or receivable by Lender with respect to such Loans. Said additional costs and/or reductions will be those which directly result from the imposition of such requirement or condition on the making or maintaining of such Loans.

  • Quality Requirements Performance Indicator Heading Indicator (specific) Threshold Method of Measurement Frequency of monitoring Consequence of Breach QUALITY Patient Safety - Incidents I1 Number of incidents Adverse incidents include the following: clinical or non clinical adverse events that have potential to cause avoidable harm to a patient, including medical errors or adverse events related to medical devices or other equipment. Clinical or non- clinical accidents, accidental injuries to staff and members of the public, verbal, physical or psychological abuse or harassment, unusual or dangerous occurrences, damage to trust property, plant or equipment, fire or flood, security, theft or loss, near misses are identified as any event where under different circumstances significant injury or loss may have occurred Number of recorded incidents in the contract month Monthly Remedial Action Plan brought to Performance Meeting following breach; action under Module C Clause 32 if needed I2 Number of Sis Definition of SUI according to trust policy and national guidance Number of Serious Untoward Incidents reported in contract month Monthly Remedial Action Plan brought to Performance Meeting following breach; action under Module C Clause 32 if needed S1 Percentage of eligible staff received child safeguarding training at level 2 (as identified in LSCB training strategy) 95% Number received training/ Number of identified staff requiring training Monthly S2 Percentage of eligible staff received adult safeguarding awareness training at level 2 ( as identified in K&M Safeguarding Vulnerable Adults training strategy) 95% Number of staff trained/ Number of identified staff requiring training Monthly

  • Standards Any additions, modifications, or replacements made to a Party’s facilities shall be designed, constructed and operated in accordance with this Agreement, NYISO requirements and Good Utility Practice.

  • Technical Requirements 2.7.4.1 The NID shall provide an accessible point of interconnection and shall maintain a connection to ground.

  • Quality Standards Each Party agrees that the nature and quality of its products and services supplied in connection with the other Party's Marks will conform to quality standards set by the other Party. Each Party agrees to supply the other Party, upon request, with a reasonable number of samples of any Materials publicly disseminated by such Party which utilize the other Party's Marks. Each Party will comply with all applicable laws, regulations, and customs and obtain any required government approvals pertaining to use of the other Party's marks.

  • Compliance with Applicable Laws and Regulations (a) The Company shall not be required to issue or deliver any Shares pursuant to this Agreement pending compliance with all applicable federal and state securities and other laws (including any registration requirements or tax withholding requirements) and compliance with the rules and practices of any stock exchange upon which the Company’s Shares are listed.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, Registration Statement, the Pricing Disclosure Package or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with applicable laws, rules, regulations and policies of the Food and Drug Administration of the U.S. Department of Health and Human Services (the “FDA”) or any committee thereof or of any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are materially inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Pricing Disclosure Package or the Prospectus; for such studies that have been or are being conducted, the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by foreign government or drug or medical device regulatory agencies, or foreign health care facility Institutional Review Boards; and no investigational new drug application filed by or on behalf of the Company or any of its subsidiaries with the FDA has been terminated or suspended by the FDA, and neither the FDA nor any applicable foreign regulatory agency has commenced, or, to the knowledge of the Company, threatened to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend, any proposed or ongoing studies conducted or proposed to be conducted by or on behalf of the Company or any of its subsidiaries.

Time is Money Join Law Insider Premium to draft better contracts faster.